Nov 05, 2025 • GlobeNewswire
NEUTRAL
HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- HUTCHMED ( China ) Limited ( "HUTCHMED" ) ( Nasdaq/AIM:HCM. HKEX:13 ) today announces the completion of patient enrollment of SAFFRON, a global Phase III study of ORPATHYS® ( savolitinib ) and TAGRISSO® ( ...
Nov 03, 2025 • Business Insider
NEUTRAL
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
- HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action - - Progress in global and China trials, including FRUSICA-2, SANOVO, surufatinib's PDAC and fanregratinib's IHCC studies, advances HUTCHMED's late-stage pipeline -
Nov 03, 2025 • GlobeNewswire
NEUTRAL
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
- HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action ...
Nov 03, 2025 • Benzinga
NEUTRAL
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event - HUTCHMED ( China ) ( NASDAQ:HCM )
- HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action - - Lead candidate HMPL-A251 harnesses a selective PI3K/PIKK inhibitor payload, demonstrating promising preclinical efficacy and safety -
Oct 31, 2025 • Benzinga
NEUTRAL
CORRECTION -- International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 04, 2025 - Belite Bio ( NASDAQ:BLTE ) , 51 Talk Online Education ( AMEX:COE )
NEW YORK, Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- In a release issued yesterday October 30, 2025 by Virtual Investor Conferences, please note several agenda items were modified. The corrected release follows:
Oct 23, 2025 • GlobeNewswire
NEUTRAL
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities ...